Pharmacological profile of the novel, potent and selective peptide leukotriene antagonist (E)-2,2-diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid.

In this report, the in vitro and in vivo pharmacological profile of MCI-826 ((E)-2,2-diethyl-3'-[2-[2-(4-isopropyl)thiazolyl)ethenyl] succinanilic acid, CAS 121230-22-6) is described. In isolated guinear pig ileum, MCI-826 inhibited LTD 4 (a peptide leukotriene, 10 -9 mol/l)-induced contraction in a concentration-dependent manner with and IC 50 of 6.8×10 -6 mol/l